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patients were assessed. The results were as follows: com-
plete response in 2 patients, partial response in 16, stable 
disease in 14, progressive disease in 8, and no evaluation in 
1. The confirmed ORR was 43.9% (95% confidence inter-
val 28.7–59.1%). The median progression-free survival and 
median overall survival were 4.6 and 11.3 months, respec-
tively. The most common grade 3 or 4 adverse events were 
neutropenia (37.5%), anemia (24.4%), anorexia (24.4%), 
and nausea (12.2%).
Conclusions First-line chemotherapy with mXP in Japa-
nese patients with mGC did not reach its primary objec-
tive. However, it did show a promising response rate and an 
acceptable tolerability profile.
Keywords Gastric cancer · Modified XP regimen · 
Capecitabine · Cisplatin · Chemotherapy
Abstract 
Purpose Capecitabine plus cisplatin (XP) is a standard 
therapy for metastatic gastric cancer (mGC). However, 
while results from previous phase III trials suggested that 
the cisplatin dosage should be reduced in Japanese patients, 
no clinical data exist to support this. Here, we conducted 
a multicenter study to evaluate the efficacy and safety of 
modified XP (mXP) in Japanese patients with mGC.
Methods Patients with previously untreated mGC received 
mXP (cisplatin 60 mg/m2 on day 1 plus capecitabine 
1000 mg/m2 twice daily on days 1–14) every 3 weeks. The 
primary endpoint was the Response Evaluation Criteria in 
Solid Tumors-confirmed overall response rate (ORR). A 
sample size of 40 was planned for a threshold ORR of 30% 
and an expected value of 50%, with a one-sided α of 0.05 
and a beta of approximately 0.2.
Results Forty-two patients were enrolled. One patient did 
not fulfill the eligibility criteria; therefore, a total of 41 
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Introduction
Gastric cancer is the third leading cause of cancer-associ-
ated deaths worldwide [1]. Once the disease becomes inop-
erable, the prognosis for gastric cancer is exceptionally 
poor. Most cases of inoperable advanced or metastatic gas-
tric cancer (mGC) remain incurable, and median survival is 
only 11–14 months, even for patients who undergo chemo-
therapy [2–4].
The combination of fluoropyrimidine and cisplatin is 
used worldwide for the treatment of mGC [2, 3]. Capecit-
abine is an oral fluoropyrimidine that is activated in tumor 
tissue via a three-step enzymatic conversion that culmi-
nates in the generation of thymidine phosphorylase [5]. 
Capecitabine has been shown to be effective in the treat-
ment of gastric cancer; it is also administered as a com-
bination treatment with cisplatin [6, 7]. Capecitabine plus 
cisplatin (XP) is regarded as a standard therapy for mGC. 
Globally, doses in the XP regimen consist of capecit-
abine (1000 mg/m2 twice daily on days 1–14) plus cispl-
atin (80 mg/m2 on day 1) every 3 weeks [8]. For Japanese 
patients, however, there has been no phase I trial of the 
combination XP regimen in a 3-week cycle. The pivotal 
Avastin in Gastric Cancer (AVAGAST) trial, a global phase 
III study that focused on the benefit of adding bevacizumab 
to the XP regimen for advanced gastric cancer [9], included 
94 Japanese patients who received XP alone. The median 
progression-free survival (PFS) in this Japanese XP group 
was equivalent to that of the overall chemotherapy group 
(5.7 vs. 5.3 months). In the AVAGAST trial, however, the 
cisplatin dose was reduced in the second cycle from 80 to 
60 mg/m2 in about 50% of the Japanese patients. Further-
more, a cisplatin dose reduction due to adverse events was 
reported in 79.8% of Japanese patients during the treatment 
course [10]. Accordingly, a more feasible dose for Japanese 
patients is anticipated.
Here, we develop a modified XP (mXP) regimen to 
reduce toxicity while maintaining efficacy in the treatment 
of mGC. This study was designed to evaluate the efficacy 
and safety of mXP in the clinical care of Japanese patients 
with mGC, including elderly patients. To confirm the 
safety of mXP regimens in both academic and community 
oncology practices, we performed this study across multi-




Eligibility criteria were: age > 20 years; histologically 
confirmed human epidermal growth factor receptor type 2 
negative unresectable or recurrent gastric cancer; Eastern 
Cooperative Oncology Group (ECOG) performance status 
<2; one or more measurable tumor lesions according to the 
Response Evaluation Criteria in Solid Tumors (RECIST) 
guidelines [11]; estimated life expectancy ≥3 months; and 
adequate organ function, as defined by hemoglobin (Hb) 
≥9 g/dL, white blood cell count ≥3000/mm3 ≤ 12,000/
mm3, absolute neutrophil count (ANC) ≥1500/mm3, 
platelet count ≥100,000/mm3, total bilirubin ≤2.0 mg/dL, 
serum transaminase level ≤100 U/L, serum creatinine level 
≤1.50 mg/dL, and creatinine clearance ≥50 mL/min. Adju-
vant chemotherapy was allowed if >6 months had elapsed 
between the end of the therapy and the registration. Exclu-
sion criteria were as follows: contraindication to any drug 
contained in the chemotherapy regimen; evidence of prior 
history of platinum administration; insufficient oral intake; 
synchronous or previous malignancy other than carcinoma 
in situ; severe comorbidities; active bleeding from the 
digestive tract; uncontrolled infection; severe mental disor-
der; pregnancy or lactation; and brain metastasis.
This trial was carried out in accordance with the Hel-
sinki Declaration and Good Clinical Practice guidelines 
and was approved by the institutional review boards of 
all participating institutions. All patients were required to 
give written informed consent before entering the study. 
The Kyushu Study Group of Clinical Cancer (KSCC) Data 
Center conducted the data management, central monitor-
ing, and statistical analysis.
Study design and treatment
Protocol treatment was defined as chemotherapy consist-
ing of capecitabine and cisplatin. Patients received capecit-
abine (1000 mg/m2 twice daily on days 1–14) plus cisplatin 
(60 mg/m2 on day 1) every 3 weeks. Following capecit-
abine administration on days 1–14, there was a 1-week rest 
period. Treatment was repeated until disease progression, 
unacceptable toxicity, or withdrawal of consent.
To prevent chemotherapy-induced nausea and vomit-
ing, the 5-hydroxytryptamine-3 receptor antagonist dexa-
methasone [9.9 mg, intravenous (i.v.)] and the selective 
neurokinin-1 neurotransmitter receptor antagonist aprepi-
tant [125 mg, per os (p.o)] were administered 1.5 h before 
chemotherapy on day 1. Aprepitant (80 mg p.o.) and dexa-
methasone (8 mg p.o.) were administered on days 2 and 3. 
Prophylactic use of granulocyte colony-stimulating factor 
was not allowed.
The dose was modified for each patient based on 
hematologic or non-hematologic toxicity. Treatment was 
delayed if, on the planned day of treatment, laboratory 
results included the following: ANC < 1500/mm3, platelets 
<75,000/mm3, Hb < 9 g/dL, serum transaminase >100 U/L, 
total bilirubin >2.0 mg/dL, serum creatinine >1.50 mg/
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dL, or if symptomatic toxicity was present. In the event 
of National Cancer Institute Common Terminology for 
Adverse Events (NCI-CTC) grade 4 neutropenia/leucope-
nia, or grade 3 or higher febrile neutropenia/thrombocy-
topenia/diarrhea/stomatitis, the capecitabine and cisplatin 
doses were reduced by 1 dose level starting at the next 
cycle. Capecitabine and cisplatin doses could be reduced by 
400 mg/m2/day and 10 mg/m2, respectively, for each level. 
Patients who could not tolerate cisplatin could continue to 
receive capecitabine monotherapy until disease progression 
or intolerable toxicity. Capecitabine could be reduced by 2 
dose levels, but treatment was discontinued if subsequent 
reduction was indicated. In the event of grade 4 non-hema-
tologic toxicities, treatment was definitively interrupted.
Study assessment
Pretreatment evaluation included: medical history; physi-
cal examination; complete blood cell count and serum 
chemistry tests; esophagogastroduodenoscopy; and chest, 
abdominal, and pelvic computed tomography (CT) scans. 
Complete blood cell counts with differential and serum 
biochemistry analyses were repeated at each treatment 
cycle. Response was assessed radiologically every 2 cycles 
or when progression was suspected. The same radiologic 
method used to document disease at baseline was used at 
subsequent assessments. No independent radiologic review 
was performed. All adverse events experienced during the 
study were recorded and graded according to the NCI-CTC 
guidelines (CTCAE version 4.0).
Endpoints and statistical analysis
The primary endpoint was overall response rate (ORR) 
according to the Response Evaluation Criteria in Solid 
Tumors (RECIST) criteria v1.0. Complete response (CR) 
and partial response (PR) were confirmed by reassessment 
on CT scans after at least another 4 weeks. Secondary end-
points included PFS, overall survival (OS), time to treatment 
failure (TTF), time to failure of strategy (TFS), and safety.
The previous phase III study showed that the ORR of 
XP for gastric cancer was 46% [8]. Furthermore, in the 
AVAGAST study, the ORR in the Japanese XP group was 
49.2% [10]. Therefore, we calculated that 35 patients were 
required to achieve 80% power to reject the null hypoth-
esis of ORR ≤ 30%, assuming that the true ORR was 50%, 
using a one-sided α of 0.05 based on the normal approxi-
mation for binomial distribution. Taking into consideration 
the dropout rate, the number of patients enrolled was 40.
The survival curve was estimated using the Kaplan–
Meier method, and 95% CI was estimated using the 
Brookmeyer and Crowley method. Safety and efficacy 
analyses were both conducted on a full analysis set (FAS) 
population, which was defined as all patients enrolled in 
the study that fulfilled the eligibility criteria and received 
chemotherapy at least once. PFS was defined as the time 
from the date of enrollment to the first documentation of 
disease progression or death. OS was determined from the 
date of enrollment to the date of death or last confirmed 
date of survival. TTF was defined as the time from the 
date of enrollment to the discontinuation of protocol treat-
ment, first documentation of disease progression, or death. 
TFS was defined as the time from the date of enrollment to 
second-line chemotherapy initiation, first documentation of 
disease progression, or death. All statistical analyses were 
performed with SAS version 9.4 (SAS Institute, Cary, NC).
This trial was registered with University Hospital Medi-
cal Information Network (No. UMIN:000006668).
Results
Patient characteristics
Forty-two patients were enrolled in this study from Novem-
ber 2011 to October 2013. Among them, 1 patient was 
excluded from all analyses due to failure to fulfill the eli-
gibility criteria. Accordingly, 41 patients were included in 
the FAS population and analyzed (Table 1). Fifteen patients 
(36.3%) had undergone resection of the primary tumor: 
total gastrectomy in 9 patients and other surgeries in 6. 
Five patients had received prior neoadjuvant and/or adju-
vant chemotherapy, while 36 patients had received no prior 
chemotherapy.
Treatment
At the data cutoff date, treatment was ongoing in just 2 
patients. The major reasons for discontinuation of treatment 
in the remaining 39 patients were disease progression in 21 
(54%) patients, adverse events in 11 (28%), surgical resec-
tion for the primary lesion or radiotherapy in 4 (10%), and 
other reasons in 3 (8%). Adverse events that required treat-
ment discontinuation included digestive symptoms (ano-
rexia/nausea/vomiting; n = 4), fatigue (n = 2), depressed 
level of consciousness (n = 1), hand–foot syndrome (HFS; 
n = 1), severe neutropenia (n = 1), renal impairment 
(n = 1), and a thromboembolic event (n = 1). The median 
relative dose intensity (RDI) was 83.7% [95% confidence 
interval (CI) 50.6–101.0%] for cisplatin and 70.1% (95% 
CI 48.6–109.2%) for capecitabine.
Efficacy
The ORR was 43.9% (95% CI 28.7–59.1%), with CR in 2 
patients and PR in 16 patients (Table 2). The disease control 
150 Cancer Chemother Pharmacol (2017) 79:147–153
1 3
rate was 78.0% (95% CI 65.4–90.7%). With a median 
follow-up period of 9.6 months (range 1.9–30.2 months), 
median PFS, median TFS, median TTF, and median OS 
were 4.6 months (95% CI 3.9–6.5), 4.4 months (95% CI 
2.5–5.3), 4.0 months (95% CI 2.3–4.9) and 11.3 months 
(95% CI 7.7–14.3), respectively (Figs. 1, 2).
Safety
The worst toxicities experienced throughout the treatment 
period are listed in Table 3. The most common grade 3 or 
higher hematologic toxicities were neutropenia (37.5%) 
and anemia (24.4%). The most common grade 3 or higher 
non-hematologic toxicities were anorexia (24.4%) and nau-
sea (12.2%). HFS occurred in 46.3% of patients; grade 3 or 
higher HFS occurred in 7.3% of patients. Febrile neutro-
penia occurred in 2 patients, but they recovered with con-
servative therapy and the protocol treatment could be con-
tinued. There were no treatment-related deaths.
Table 1  Patient characteristics (n = 41)
ECOG Eastern Cooperative Oncology Group, PS performance status, 
HER2 human epidermal growth factor receptor type 2, IHC immuno-
histochemistry, FISH fluorescence in situ hybridization
Variable n (%)
Age (years)
 Median (range) 64 (50–81)
Sex
 Male 34 82.9
 Female 7 17.1
ECOG PS
 0 33 80.5
 1 8 19.5
Primary tumor location
 U 12 29.3
 M 19 46.3
 L 10 24.4
Histology of primary tumor
 Well 18 43.9
 Poorly 22 53.7
 Other 1 2.4
HER2 status
 IHC 0/1+ 37 90.2
 IHC 2+/FISH negative 4 9.8
Disease status
 Advanced 28 68.3
 Recurrent 13 31.7
Sites of metastasis
 Liver 17 41.5
 Lungs 1 2.4
 Lymph node 32 78.0
 Peritoneum 12 29.3
 Other 7 17.0
Table 2  Treatment response rate (n = 41)
CI confidence interval
Variable n % (95% CI)
Complete response 2 4.9 (0.1–16.5)
Partial response 16 39.0 (24.2–55.5)
Stable disease 14 34.1 (20.1–50.6)
Progressive disease 8 19.5 (8.8–34.9)
Not evaluated 1 2.4 (0.0–12.9)
Overall response rate 18 43.9 (28.7–59.1)
Disease control rate 32 78.9 (65.4–90.7)
Fig. 1  Progression-free survival (n = 41)
Fig. 2  Overall survival (n = 41)
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Discussion
In this study, we found that the mXP regimen was active 
and tolerable as first-line chemotherapy in patients with 
mGC. Previous studies of the XP regimen in patients with 
mGC reported an ORR of 35–37.4% with a median PFS 
of 5.3–5.5 months and a median OS of 10.1–11.1 months 
[9, 12]. The efficacy in our study was equivalent to that of 
these previous studies, with an ORR of 43.9%, median PFS 
of 4.6 months, and median OS of 11.3 months, although 
the actual ORR was lower than the expected ORR (50%). 
To our knowledge, this is the first multicenter prospective 
study of capecitabine plus cisplatin as first-line chemother-
apy for Japanese patients with mGC.
One reason for the lower than expected efficacy may 
be the comparatively lower dose intensity of capecitabine 
and the lower dose of cisplatin. In the AVAGAST study, the 
RDI of capecitabine was 80% in the Japanese XP group 
and 87% in the overall XP group. In contrast, with the mXP 
regimen, the RDI of capecitabine was 70.1%. As a result, 
the frequency of HFS in this study was lower than that in 
a previous report (57 vs. 46%) [10]. Lotions are currently 
recommended to improve moisturization and patients 
receive instructions on how to prevent adverse effects, such 
as heat exposure, and to reduce friction; therefore, the dose 
intensity is expected to be higher. This study shows that the 
mXP regimen maintained an RDI of cisplatin of 83.7 versus 
71% in both the Japanese XP group and overall XP group 
in the AVAGAST study. This means that 16.7 mg/m2/week 
of cisplatin was actually administered in the mXP regimen, 
while 18.9 mg/m2/week was administered in the AVAGAST 
trial. Furthermore, treatment discontinuation due to adverse 
events occurred in only 6–7% in the Japanese XP group in 
the AVAGAST study, versus 28% in the present study. We 
planned the mXP regimen by modifying the cisplatin dose 
to improve dose intensity and ensure safety in the cohort 
of Japanese patients. However, the lower dose intensity of 
capecitabine, the lower dose of cisplatin, and treatment dis-
continuation due to adverse events may explain why this 
study did not reach the expected ORR. Table 4 shows a his-
torical comparison of first-line chemotherapies consisting 
of capecitabine plus cisplatin for mGC.
Compared with previous reports, severe toxicities were 
not commonly observed with the mXP regimen in the 
current study. In the AVAGAST study, grade 3 or higher 
adverse events in a Japanese XP group included neutro-
penia (48%), anorexia (29%), nausea (19%), and anemia 
(11%) [10]. In the present study, lower incidence rates of 
these adverse advents were observed: neutropenia, 37.5%; 
anorexia, 24.4%; nausea, 12.2%; and anemia, 2.4%. 
Table 3  Maximum toxicity per 
patient (n = 41)
NCI-CTC National Cancer Institute Common Toxicity Criteria
Adverse event NCI-CTC grade
1 2 3 4 All (%) 3–4 (%)
Hematologic, n
 Leukopenia 8 15 7 0 73.2 17.1
 Neutropenia 8 7 13 2 75.0 37.5
 Anemia 13 17 10 0 97.6 24.4
 Thrombocytopenia 20 3 1 0 58.5 2.4
Non-hematologic, n
 Alopecia 3 0 – – 7.3 0
 Anorexia 13 8 10 0 75.6 24.4
 Depressed level of consciousness 0 0 1 0 2.4 2.4
 Diarrhea 4 2 0 0 14.6 0
 Dysgeusia 6 4 – – 24.4 0
 Fatigue 10 14 4 0 68.3 9.8
 Febrile neutropenia – – 2 0 4.9 4.9
 Hand–foot syndrome 10 6 3 0 46.3 7.3
 Nausea 10 10 5 0 61.0 12.2
 Peripheral sensory neuropathy 6 3 0 0 22.0 0
 Renal impairment 7 0 0 0 17.1 0
 Skin hyperpigmentation 13 0 – – 31.7 0
 Stomatitis 10 3 1 0 34.1 2.4
 Thromboembolic event 0 0 1 0 2.4 2.4
 Vomiting 5 2 3 0 24.4 7.3
152 Cancer Chemother Pharmacol (2017) 79:147–153
1 3
Moreover, about 50% of the Japanese patients in the AVA-
GAST study required a cisplatin dose reduction during the 
second treatment cycle, and 79.8% of patients required a 
cisplatin dose reduction due to adverse events at some 
point during the treatment course [10]. In contrast, grade 
3 or higher toxicities during the first treatment cycle in the 
present study were neutropenia (n = 10), anemia (n = 2), 
thrombocytopenia (n = 1), anorexia (n = 4), nausea/vomit-
ing (n = 3), stomatitis (n = 1), fatigue (n = 1), and febrile 
neutropenia (n = 2), while only 15 patients (37%) required 
a dose reduction during the second treatment cycle. In 
other words, the safety profile of the mXP regimen appears 
promising. On the contrary, mild bone suppression might 
mean that the dose of cisplatin is insufficient.
Several limitations of our study warrant mention. We 
did not perform a phase I study to determine the dose of 
cisplatin in the XP regimen for Japanese patients with 
gastric cancer, so the optimum cisplatin dose remains 
unclear. We set the cisplatin dose in the current study at 
60 mg/m2 based on the S-1 plus cisplatin (SP) regimen [3, 
13] and a previous phase 2 study of XP for gastric cancer 
[7]. The optimal dose of capecitabine, when administered 
as a monotherapy, is 1250 mg/m2 twice daily, on days 
1–14, every 3 weeks [14]. Additionally, a previous phase 
2 study administered capecitabine at 1250 mg/m2, twice 
daily, on days 1–14 plus cisplatin at 60 mg/m2 i.v. on day 
1, repeated every 3 weeks [7]. However, the standard XP 
regimen for mGC now consists of capecitabine (1000 mg/
m2, twice daily, on days 1–14) plus cisplatin (80 mg/m2 on 
day 1) every 3 weeks [8]. This means that the standard XP 
regimen consists of a decreased capecitabine dose and an 
increased cisplatin dose, compared with previous studies. 
When combined with cisplatin, both S-1 and capecitabine 
are orally administered with fluoropyrimidines to ensure 
efficacy in the treatment of gastric cancer. However, the 
recommended dose of cisplatin in a combination treatment 
depends on the combination: 60 mg/m2 cisplatin for the SP 
regimen and 80 mg/m2 cisplatin for the XP regimen. Fur-
thermore, the present study did not reach its primary objec-
tive. This might mean that the anti-tumor effect of cisplatin 
in the XP regimen is more dose-dependent than that of 
cisplatin in the SP regimen, so we should have discussed 
the modification of cisplatin dose further. Preclinical stud-
ies demonstrated the indirect role of cisplatin as a modula-
tor for fluorouracil (5-FU), in addition to its direct effect 
as an effector [15, 16]. S-1 is a novel oral fluoropyrimidine 
consisting of a 5-FU prodrug, tegafur, a dihydropyrimidine 
dehydrogenase inhibitor, 5-chloro-2,4-dihydroxypyridine, 
and the orotate phosphoribosyl-transferase inhibitor, potas-
sium oxonate, which suppresses the gastrointestinal tox-
icity of tegafur [17]. In contrast, capecitabine is an oral 
fluoropyrimidine that is metabolized primarily in the liver 
and converted in tumor tissues to 5-FU by the enzyme thy-
midine phosphorylase, which is present in higher concen-
trations in tumor cells than in normal cells [18]. The dif-
ferences between S-1 and capecitabine may affect the role 
of cisplatin in each regimen. In the present study, only 1 
patient did not experience grade 3 or higher toxicities dur-
ing treatment; in other words, this patient might have been 
disadvantaged by the mXP regimen because the cisplatin 
reduction may have been unnecessary.
In conclusion, although the present study did not reach 
its primary objective, the mXP regiment showed promis-
ing efficacy and an acceptable tolerability profile in clinical 
practice. The modified XP regimen is a treatment option for 
patients with mGC.
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